 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | Derazol DDR (dexrabeprazole) / Neutec
Journal: Reply to the letter to the editor "Clarifications on the safety of dexrabeprazole vs. omeprazole in the treatment of gastroesophageal reflux disease". (Pubmed Central) - Sep 16, 2023
No abstract available
- | Derazol DDR (dexrabeprazole) / Neutec
Journal: Clarifications on the safety of dexrabeprazole vs. omeprazole in the treatment of gastroesophageal reflux disease. (Pubmed Central) - Sep 16, 2023
No abstract available No abstract available
- | Derazol DDR (dexrabeprazole) / Neutec
Journal: Efficacy and safety comparative study of dexrabeprazole vs. esomeprazole for the treatment of gastroesophageal reflux disease. (Pubmed Central) - Jan 20, 2023
No abstract available In the treatment of non-erosive GERD, the use of dexrabeprazole at 10 mg/day is as effective as esomeprazole 20 mg/day, with the advantage that the dose is lower with an appropriate safety profile.
- Derazol DDR (dexrabeprazole) / Neutec
THE EFFECT OF DEXRABEPRAZOLE ON INTRAGASTRIC AND INTRAESOPHAGEAL ACIDITY AND SYMPTOMS OF GASTROESOPHAGEAL REFLUX DISEASE (Poster Stage 4) - Jul 20, 2022 - Abstract #UEGW2022UEGW_1241;
The agent was more effective than rabeprazole in reducing the 24-hour intraesophageal pH<4. Besides, it was observed that its effect on regurgitation started earlier than rabeprazole which is known with its quick effect.
- || Derazol DDR (dexrabeprazole) / Neutec, tenatoprazole (sTU-199) / Mitsubishi Tanabe
Review, Journal: Determination of Proton Pump Inhibitors by Spectrophotometric, Chromatographic and by Hyphenated Techniques: A Review. (Pubmed Central) - Oct 27, 2021
The examined literature survey addressed chromatographic (HPLC and UPLC) and UV visible spectrophotometric methods with LC-MS/MS methods used in pure forms, pharmaceutical formulations, and human plasma and other biological fluids for their estimation. In case of validation parameters mostly Linearity, Recovery study, LOD and LOQ was considered and mentioned.
- | lansoprazole / Generic mfg.
Journal: Chiral separation of lansoprazole and rabeprazole by capillary electrophoresis using dual cyclodextrin systems. (Pubmed Central) - Mar 31, 2020
The optimized methods (25 mM phosphate buffer, pH = 7.0, 10 mM sulfobutyl-ether-β-CD/20 mM γ-CD, +20 kV voltage; 17°C temperature; 50 mbar/3 s injection, detection at 210 nm for lansoprazole; 25 mM phosphate buffer, pH = 7.0, 15 mM sulfobutyl-ether-β-CD/30 mM γ-CD, +20 kV voltage; 18°C temperature; 50 mbar/3 s injection, detection at 210 nm for rabeprazole) provided baseline separation for lansoprazole (Rs = 2.91) and rabeprazole (Rs = 2.53) enantiomers with favourable migration order (in both cases the S-enantiomers migrates first). The optimized methods were validated according to current guidelines and proved to be reliable, linear, precise and accurate for the determination of 0.15% distomer as chiral impurity in dexlansoprazole and dexrabeprazole samples .
- | Derazol DDR (dexrabeprazole) / Neutec
Trial completion: The Effect of Dexrabeprazole on Intragastric and Intraesophageal Acidity (clinicaltrials.gov) - Aug 24, 2017
P4, N=12, Completed, Sponsor: Neutec Ar-Ge San ve Tic A.?
The optimized methods were validated according to current guidelines and proved to be reliable, linear, precise and accurate for the determination of 0.15% distomer as chiral impurity in dexlansoprazole and dexrabeprazole samples . Recruiting --> Completed
- | Derazol DDR (dexrabeprazole) / Neutec
Trial primary completion date: The Effect of Dexrabeprazole on Intragastric and Intraesophageal Acidity (clinicaltrials.gov) - May 25, 2017
P4, N=12, Recruiting, Sponsor: Neutec Ar-Ge San ve Tic A.?
Recruiting --> Completed Trial primary completion date: Mar 2017 --> Jun 2017
- Derazol DDR (dexrabeprazole) / Neutec
Enrollment open: The Effect of Dexrabeprazole on Intragastric and Intraesophageal Acidity (clinicaltrials.gov) - Jul 23, 2016
P4, N=12, Recruiting, Sponsor: Neutec Ar-Ge San ve Tic A.?
Trial primary completion date: Mar 2017 --> Jun 2017 Active, not recruiting --> Recruiting
- Derazol DDR (dexrabeprazole) / Neutec
New P4 trial: The Effect of Dexrabeprazole on Intragastric and Intraesophageal Acidity (clinicaltrials.gov) - Feb 24, 2016
P4, N=12, Active, not recruiting, Sponsor: Neutec Ar-Ge San ve Tic A.?